스핑고신1-인산 수용체(S1PR) 조절제 시장 보고서(2026년)

Sphingosine-1-phosphate receptor (S1PR) modulator drugs are a category of therapeutic agents designed to selectively act on sphingosine-1-phosphate (S1P) receptors, which belong to a family of G-protein-coupled receptors that regulate essential cellular functions. These agents influence S1P receptor activity, which is central to immune cell movement, vascular regulation, and inflammatory responses.

The primary types of sphingosine 1 phosphate receptor (S1PR) modulator drugs include fingolimod and ozanimod. Fingolimod is an orally administered therapy used for the management of multiple sclerosis (MS) by regulating immune system activity to reduce nerve damage associated with the condition. These medications are offered through multiple routes of administration, such as oral, injectable, and topical formulations, and are utilized in treating multiple sclerosis, cardiovascular disorders, and transplant rejection. They are mainly distributed and used across hospitals, rehabilitation facilities, and retail pharmacies.

Tariffs have raised the cost of specialty APIs used in the manufacturing of S1PR modulators for oral capsule formulations. These impacts are most evident in Europe and Asia Pacific, where producers rely on cross border sourcing for complex synthesis inputs. Rising tariff related expenses have influenced production costs, pricing strategies, and availability of oral capsule therapies. This has affected procurement planning and supply continuity for neurological and autoimmune treatments. Positively, tariffs are supporting regional production, expanded local API manufacturing, and greater supply chain diversification over the long term.

The sphingosine 1 phosphate receptor (s1pr) modulator drugs market research report is one of a series of new reports from The Business Research Company that provides sphingosine 1 phosphate receptor (s1pr) modulator drugs market statistics, including sphingosine 1 phosphate receptor (s1pr) modulator drugs industry global market size, regional shares, competitors with a sphingosine 1 phosphate receptor (s1pr) modulator drugs market share, detailed sphingosine 1 phosphate receptor (s1pr) modulator drugs market segments, market trends and opportunities, and any further data you may need to thrive in the sphingosine 1 phosphate receptor (s1pr) modulator drugs industry. This sphingosine 1 phosphate receptor (s1pr) modulator drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sphingosine 1 phosphate receptor (s1pr) modulator drugs market size has grown strongly in recent years. It will grow from $2.57 billion in 2025 to $2.72 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to clinical success of fingolimod, rising autoimmune disease prevalence, expansion of neurology treatment protocols, hospital-based immunotherapy adoption, regulatory approvals for s1pr drugs.

The sphingosine 1 phosphate receptor (s1pr) modulator drugs market size is expected to see strong growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growing multiple sclerosis patient population, expansion of s1pr drug pipelines, increased preference for oral immunotherapies, rising autoimmune disease diagnosis rates, growing specialty clinic adoption. Major trends in the forecast period include growing use of immune cell trafficking modulators, increasing adoption in multiple sclerosis treatment, expansion of oral immunomodulatory therapies, rising focus on targeted immune modulation, increased use in chronic autoimmune conditions.

The growing incidence of autoimmune disorders is anticipated to drive the expansion of the sphingosine 1-phosphate receptor (S1PR) modulator drugs market in the coming years. Autoimmune disorders occur when the immune system incorrectly targets the body's own healthy tissues, leading to inflammation and tissue damage. The increasing occurrence of these conditions is attributed to a combination of genetic predisposition, environmental influences, lifestyle-related factors, and advances in diagnostic capabilities. Sphingosine 1-phosphate receptor (S1PR) modulator drugs are used in the management of autoimmune conditions by controlling immune cell movement, thereby lowering inflammation in diseases such as multiple sclerosis and ulcerative colitis. For example, in February 2025, data reported by the Australian Broadcasting Corporation, a national public broadcaster in Australia, indicated that inflammatory bowel disease affects nearly 180,000 people in the country, including 93,700 individuals with Crohn's disease and 80,430 with ulcerative colitis, with projections suggesting the total could reach 200,000 within the next decade. As a result, the rising prevalence of autoimmune diseases is contributing to the growth of the sphingosine 1-phosphate receptor (S1PR) modulator drugs market.

Major companies operating in the sphingosine-1-phosphate receptor (S1PR) modulator drugs space are progressing oral treatment options, including etrasimod (VELSIPITY), to improve patient compliance, strengthen therapeutic effectiveness, and broaden applicability across immuno-inflammatory conditions. An oral S1PR modulator is a small-molecule tablet designed to selectively interact with S1P receptors, regulating immune cell movement and limiting inflammatory responses. For example, in October 2023, Pfizer, a US-based pharmaceutical and biotechnology company, obtained FDA approval for VELSIPITY (etrasimod) to treat moderately to severely active ulcerative colitis; this once-daily therapy provides high receptor specificity, a positive safety profile, and the convenience of oral administration.

In December 2023, Vanda Pharmaceuticals, a US-based pharmaceutical company, obtained the U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd. for an undisclosed sum. This transaction is intended to strengthen Vanda's product portfolio by adding a novel treatment for relapsing multiple sclerosis, a disease marked by rising prevalence and substantial unmet clinical needs. Actelion Pharmaceuticals Ltd. is a Switzerland-based biopharmaceutical firm specializing in the development of sphingosine 1-phosphate receptor (S1PR) modulator therapies for a range of medical conditions.

Major companies operating in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market are Novartis International AG, Bristol Myers Squibb Company, Celgene Corporation, Biogen Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Ventyx Biosciences Inc., Arena Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., KYORIN Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., Vanda Pharmaceuticals Inc., Juvise Pharmaceuticals, Priothera Limited, Teva Pharmaceutical Industries Ltd.

Asia-Pacific was the largest region in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market in 2025. The regions covered in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market consists of sales of non-selective S1PR modulators, selective S1PR1 modulators, and next-generation and experimental S1PR modulators. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses sphingosine 1 phosphate receptor (s1pr) modulator drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sphingosine 1 phosphate receptor (s1pr) modulator drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sphingosine 1 phosphate receptor (s1pr) modulator drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Fingolimod; Ozanimod
• 2) By Route Of Administration: Oral; Injectable
• 3) By Application: Multiple Sclerosis; Cardiovascular Diseases; Transplant Rejection
• 4) By End User: Hospital; Rehabilitation Centres; Retail Pharmacies
• Subsegments:
• 1) By Fingolimod: Branded Formulations; Generic Formulations
• 2) By Ozanimod: Oral Capsules; Other Formulations
• Companies Mentioned: Novartis International AG; Bristol Myers Squibb Company; Celgene Corporation; Biogen Inc.; Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Johnson & Johnson; Ventyx Biosciences Inc.; Arena Pharmaceuticals; Idorsia Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.; Eisai Co. Ltd.; Ono Pharmaceutical Co. Ltd.; KYORIN Pharmaceutical Co. Ltd.; Actelion Pharmaceuticals Ltd.; Vanda Pharmaceuticals Inc.; Juvise Pharmaceuticals; Priothera Limited; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Growing Use Of Immune Cell Trafficking Modulators
  • 4.2.2 Increasing Adoption In Multiple Sclerosis Treatment
  • 4.2.3 Expansion Of Oral Immunomodulatory Therapies
  • 4.2.4 Rising Focus On Targeted Immune Modulation
  • 4.2.5 Increased Use In Chronic Autoimmune Conditions

5. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Neurology Clinics
• 5.3 Specialty Clinics
• 5.4 Retail Pharmacies
• 5.5 Rehabilitation Centers

6. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Segmentation

• 9.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Fingolimod, Ozanimod
• 9.2. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable
• 9.3. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Multiple Sclerosis, Cardiovascular Diseases, Transplant Rejection
• 9.4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital, Rehabilitation Centres, Retail Pharmacies
• 9.5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Sub-Segmentation Of Fingolimod, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Branded Formulations, Generic Formulations
• 9.6. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Sub-Segmentation Of Ozanimod, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral Capsules, Other Formulations

10. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Regional And Country Analysis

• 10.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 11.1. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 12.1. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 13.1. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 14.1. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 15.1. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 16.1. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 17.1. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 18.1. Taiwan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 19.1. South East Asia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 20.1. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 21.1. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 22.1. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 23.1. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 24.1. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 25.1. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 26.1. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 27.1. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 28.1. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 29.1. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 30.1. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 31.1. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 32.1. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 33.1. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 34.1. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Regulatory and Investment Landscape

36. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Landscape And Company Profiles

• 36.1. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Company Profiles
  • 36.3.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Other Major And Innovative Companies

• Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Ventyx Biosciences Inc., Arena Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., KYORIN Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., Vanda Pharmaceuticals Inc., Juvise Pharmaceuticals, Priothera Limited, Teva Pharmaceutical Industries Ltd.

38. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

40. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer